4.6 Article

Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor Clinical article

期刊

JOURNAL OF NEUROSURGERY
卷 117, 期 1, 页码 156-161

出版社

AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2012.3.JNS112316

关键词

essential tremor; deep brain stimulation; quality of life; thalamic stimulation; functional neurosurgery

资金

  1. Novartis
  2. Impax
  3. Merck Serono
  4. Boehringer Ingelheim
  5. Schering Plough
  6. Adamas
  7. Phytopharm
  8. Biotie
  9. Allon
  10. Acadia
  11. Xenoport

向作者/读者索取更多资源

Object. The goal of this study was to evaluate short- and long-term benefits in quality of life (QOL) after unilateral deep brain stimulation (DBS) for essential tremor (ET). Methods. Patients who received unilateral DBS of the ventral intermediate nucleus of the thalamus between 1997 and 2010 and who had at least 1 follow-up evaluation at least I year after surgery were included. Their QOL was assessed with the Parkinson Disease Questionnaire-39 (PDQ-39), and ET was measured with the Fahn-Tolosa-Marin tremor rating scale (TRS) prior to surgery and then postoperatively with the stimulation in the on mode. Results. Ninety-one patients (78 at 1 year; 42 at 2-7 years [mean 4 years]; and 22 at > 7-12 years [mean 9 years]) were included in the analysis. The TRS total, targeted tremor, and activities of daily living (ADL) scores were significantly improved compared with presurgical scores up to 12 years. The PDQ-39 ADL, emotional well-being, stigma, and total scores were significantly improved up to 7 years after surgery compared with presurgical scores. At the longest follow-up, only the PDQ-39 stigma score was significantly improved, and the PDQ-39 mobility score was significantly worsened. Conclusions. Unilateral thalamic stimulation significantly reduces ET and improves ADL scores for up to 12 years after surgery, as measured by the TRS. The PDQ-39 total score and the domains of ADL, emotional well-being, and stigma were significantly improved up to 7 years. Although scores were improved compared with presurgery, other than stigma, these benefits did not remain significant at the longest (up to 12 years) follow-up, probably related in part to changes due to aging and comorbidities. (http://thejns.org/doi/abs/10.3171/2012.3.JNS112316)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据